Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
NCT ID: NCT00078195
Last Updated: 2016-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
168 participants
INTERVENTIONAL
2003-04-30
2005-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis
NCT00396409
A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)
NCT01469182
The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils
NCT00673218
Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug
NCT00318747
The Efficacy of Preseasonal Omalizumab Treatment
NCT04489121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Individuals with allergies react to harmless particles such as dust or pollen. Proteins in the blood called IgE antibodies treat the harmless particles as invaders and trigger an immune system response. The immune response results in harmful inflammation of healthy tissues. In ragweed allergy, inflammation occurs in the airways and causes familiar allergy symptoms like sneezing, coughing, and general discomfort.
Omalizumab is an investigational drug that has been shown to block the effects of IgE antibodies. The blocking effect of omalizumab is temporary, but giving the drug to people before their regular allergy shots may make the shots more effective.
Participants in this study will be randomly assigned to receive injections of omalizumab or a placebo before an accelerated course of allergy shots (given over 12 weeks). The participants will return for follow-up for up to one year, and they may have as many as 27 study visits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT
Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
omalizumab
A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
Ragweed rush immunotherapy (RIT)
RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
Ragweed immunotherapy (IT)
Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
Omalizumab pre-treatment, omalizumab
Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
omalizumab
A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
Placebo rush immunotherapy (RIT)
The placebo for rush immunotherapy will contain the diluents and histamine.
Placebo immunotherapy (IT)
The placebo for immunotherapy will contain the diluents and histamine.
Ragweed RIT, ragweed IT
Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
Placebo omalizumab
The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
Ragweed rush immunotherapy (RIT)
RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
Ragweed immunotherapy (IT)
Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
Placebo
Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
Placebo omalizumab
The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
Placebo rush immunotherapy (RIT)
The placebo for rush immunotherapy will contain the diluents and histamine.
Placebo immunotherapy (IT)
The placebo for immunotherapy will contain the diluents and histamine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
omalizumab
A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
Placebo omalizumab
The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
Ragweed rush immunotherapy (RIT)
RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
Placebo rush immunotherapy (RIT)
The placebo for rush immunotherapy will contain the diluents and histamine.
Ragweed immunotherapy (IT)
Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
Placebo immunotherapy (IT)
The placebo for immunotherapy will contain the diluents and histamine.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female participants of child bearing age must have a negative urine pregnancy test at Screening Visit and subsequent visits. In addition, female participants must be using a medically acceptable form of birth control.
* History of seasonal allergic rhinitis for at least 2 years with symptoms during the ragweed pollen season requiring pharmacotherapy.
* A positive skin test by prick method to ragweed pollen at the Screening Visit. A positive skin prick test will be defined as a ragweed pollen-induced wheal greater than 3 mm larger in diameter than diluent control (measurements will be made 15-20 minutes after application).
* Must be capable of faithfully completing the diary and of attending regularly scheduled study visits.
* Must intend to remain in the ragweed pollen area during the entire ragweed season.
* Willing to avoid prohibited medications for the periods indicated in the protocol.
* Participants must meet pretrial eligibility requirements for trial enrollment (acceptable medical history, physical examination results, normal electrocardiogram and acceptable laboratory test results).
* Participants must have a baseline serum Immunoglobulin E (IgE) level greater than 10 and less than 700 IU/mL.
Exclusion Criteria
* pregnant or lactating.
* history of severe anaphylactoid (non-IgE mediated) or anaphylactic reactions).
* history of immunotherapy within the past 10 years, if received one full year of immunotherapy, or within the past 5 years if received less than one year of immunotherapy.
* known hypersensitivity to trial rescue medication (fexofenadine HCl).
* taking beta-adrenergic antagonists in any form.
* taking allergic ophthalmologic medication.
* clinically significant perennial rhinitis that would interfere in assessment of ragweed-induced seasonal allergic rhinitis symptoms.
* Presence of a severely deviated nasal septum, septal perforation, structural nasal defect or large nasal polyps causing obstruction.
* History of an upper respiratory or sinus infection requiring treatment with an antibiotic within 2 weeks prior to Screening Visit.
* Documented evidence of acute or significant chronic sinusitis, as determined by the Investigator.
* Asthma (either history of, abnormal spirometry, \[forced expiratory volume in 1 second (FEV1) less than 80% predicted\] or use of asthma medications).
* Chronic or intermittent use of inhaled, oral, intra-muscular, or intra-venous corticosteroids; or chronic or intermittent use of topical corticosteroids within 4 weeks of Visit Screening Visit.
* Chronic use of medications (e.g., tricyclic antidepressants) that would affect assessment of the effectiveness of the study medication.
* Rhinitis medicamentosa.
* History or presence of significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal or other significant medical condition including, autoimmune or collagen vascular disorders, aside from organ-specific autoimmune disease limited to the thyroid that in the Investigator's opinion could interfere with the study or require medical treatment that would interfere with the study.
* History of cancer other than basal cell carcinoma of the skin.
* History within the past year of excessive alcohol intake or drug addiction.
* Current smokers, greater than 10 pack year history, or participants who quit smoking less than one year prior to Screening.
* Use of any prohibited concomitant medications during the washout period (i.e., before screening) and throughout the study period.
* Participants currently undergoing immunotherapy.
* Participants with clinically significant abnormality on 12-lead Electrocardiogram (ECG) on screening visit.
* Treatment with an experimental, non-approved drug, or investigational drug within the past 30 days.
* Participants with a history of noncompliance to medical regimens and participants who are considered potentially unreliable.
* Previous treatment with a monoclonal antibody for any reason including anti-IgE in any form (e.g., omalizumab).
* Participants with known hypersensitivity to trial drug ingredients (i.e., sucrose, histidine, polysorbate 20) or related drugs (i.e., monoclonal antibody; polyclonal gamma-globulin).
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Immune Tolerance Network (ITN)
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Casale, MD
Role: PRINCIPAL_INVESTIGATOR
Creighton University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Iowa
Iowa City, Iowa, United States
Creighton University
Omaha, Nebraska, United States
University of Wisconsin
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, Della Cioppa G, Gupta N. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003 Sep-Oct;24(5):323-9.
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006 Jan;117(1):134-40. doi: 10.1016/j.jaci.2005.09.036. Epub 2005 Dec 2.
Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN; Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007 Sep;120(3):688-95. doi: 10.1016/j.jaci.2007.05.034. Epub 2007 Jul 12.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Study design, -summary, -files, -interventions, participant schedule of events, -demographics, et al.
ImmPort study identifier is SDY1
View DocumentDocument Type: Individual Participant Data Set
TrialShare study identifier is CASALE ITN019AD
View DocumentDocument Type: Study protocol synopsis; -schedule of assessments; -data and reports; -specimens availability et al.
TrialShare study identifier is CASALE ITN019AD
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
National Institute of Allergy and Infectious Diseases (NIAID)
Division of Allergy, Immunology, and Transplantation (DAIT)
Immune Tolerance Network (ITN)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAIT ITN019AD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.